Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?

TheMotleyFool

0 0

Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?: https://g.foolcdn.com/editorial/images/719184/scientists-smiling-and-shaking-hands.jpg

Some might argue that Gilead Sciences (NASDAQ: GILD) is back. The stock trounced the S&P 500 in 2022. Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum.

The big drugmaker reported its 2022 full-year and fourth-quarter results after the market closed on Thursday. CEO Dan O'Day stated in the press release announcing the numbers, "2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015."

Is Gilead Sciences stock a buy after its strongest results in seven years?

Source Fool.com

Like: 0

GILD

Share